TCTR20230915004尚未招募1 期
A Bioequivalence study of a randomized, open-label, single dose, full replicate crossover design with four-period, two-treatment, and two-sequence of Fexofenadine 180 mg tablets relative to Telfast 180 mg tablets in healthy Thai volunteers under fasting condition.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Willingness to provide written informed consent prior to participate in the study.
- •2.Healthy Thai subjects are between 18 to 55 years of age.
- •3.The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
- •4.Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects safety after the completion of the study.
- •5.Negative urine pregnancy test for women and no breast-feeding.
- •6.Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
排除标准
- •1.History or evidence of allergy or hypersensitivity to Fexofenadine, Loratadine, Levocetirizine, Cetirizine, Hydroxyzine or any piperidine derivative drugs or any of the excipients of this product.
- •2.Subject with B.P. is Systolic B.P < 90, >=140 mm/Hg, Diastolic B.P < 60, >=90 mm/Hg, pulse rate > 100 beats per minute.
- •3.Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- •4.Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*
- •5.Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
- •6.Positive of hepatitis B, hepatitis C virus or HIV.
- •7.Have more than one abnormal EKG, which is considered as clinically significant. *
- •8.History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension or glaucoma.
- •9.Have any symptom of urinary retention in past 1 month e.g. inability to urinate, urgent need to urinate or a slow urine stream.
- •10.History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- •11.Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- •12.History of seizures or with conditions that lower the seizure threshold, e.g., Alzheimers dementia, severe head trauma.
- •13.History of psychiatric disorder.
- •14.History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •15.History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •16.History of grapefruit, orange, pomelo, apple or related products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •17.High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •18.Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
- •19.Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication.
- •20.History of difficulty in accessibility of veins in left and right arm.
- •21.Blood donation (one unit or 450 mL) within the past 3 months before the study.
- •22.Participation in any clinical study within the past 3 months before the study.
- •23.Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
- •(* Depend on decision of principal investigator and/or clinical investigator)
研究者
相似试验
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin Tablets 100 mg relative to Januvia (Sitagliptin Phosphate) 100 mg Tablets in healthy Thai volunteers under fasting conditioHealthy subjectsBioequivalenceSitagliptinTCTR20211008001Bio-innova and Synchron.Co.,Ltd26
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Rivaroxaban Film-Coated Tablets (20 mg) relative to Originator Rivaroxaban Film-Coated Tablets (20 mg) in healthy Thai volunteers under fed conditioHealthy subjectsBioequivalenceRivaroxabanTCTR20211018006Bio-innova and Synchron.Co.,Ltd30
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Sitagliptin and Metformin tablets 50 mg/500 mg relative to Janumet (50 MG/500 MG) in healthy Thai volunteers under fed conditioHealthy subjectsBioequivalence Sitagliptin and Metformin tablets 50 mg/500 mgTCTR20230617001Bio-innova Co., Ltd.44
尚未招募
1 期
A Bioequivalence study of a randomized open-label single dose two-way crossover design with two-period two-treatment and two-sequence of Aripiprazole 10 mg Orally Disintegrating Tablets relative to Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets in healthy Thai under fastingHealthy subjectsBioequivalence Aripiprazole 10 mg Orally Disintegrating TabletsTCTR20230503001Bio-innova Co., Ltd.30
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, 3-period, 2-treatment, 3-sequence, partial replicate, crossover study of Febuxostat Tablets (80 mg) relative to Feburic 80 mg Tablets in healthy Thai volunteers under fasting conditioTCTR20230426005Bio-innova Co., Ltd.36